Sun Pharmaceutical Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Wed Apr 01 2026

Sun Pharmaceutical Q4 Results FY26 — Board meeting on May 12, 2026 (Expected)

The Sun Pharma Q4 results 2026 is set to be one of the most closely watched earnings events of the April-May 2026 results season. With results scheduled for May 12, 2026 (Expected), investors and analysts across brokerages are building their expectations around revenue, PAT, margin trajectory, and what management will say about FY27.

Sun Pharmaceutical enters Q4 FY26 at a CMP of ~Rs. 1,680, against a 52-week high of Rs. 1,960 and a 52-week low of Rs. 1,440. The one-year return stands at -5%, making this quarter’s result and guidance commentary particularly important for investors deciding whether to hold, add, or exit.

This article covers the Sun Pharmaceutical Q4 results 2026 date, earnings estimates, key factors driving performance, five risks to watch, analyst ratings and price targets, and a full set of FAQs around what investors are searching for ahead of the announcement.

Table of Contents

Sun Pharmaceutical Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

The Sun Pharmaceutical Q4 FY26 results date is May 12, 2026 (Expected). The board of directors will meet to approve the audited financial statements for the quarter and full financial year ended March 31, 2026. The board will also consider recommending a dividend for FY26 shareholders, subject to approval at the upcoming Annual General Meeting.

Here is how the broader Q4 FY26 earnings calendar looks for large-cap Indian companies in April–May 2026:

Company	Q4 FY26 Results Date
TCS	April 9, 2026
HDFC Bank / ICICI Bank	April 18, 2026
HCL Technologies	April 21, 2026
Infosys	April 23, 2026
Sun Pharmaceutical	May 12, 2026 (Expected)

Source: BSE/NSE exchange filings, April 2026. Expected dates may change. Verify before relying.

Why This Quarter Matters

Every quarterly result tells a story, but Sun Pharmaceutical Q4 FY26 carries more weight than a routine earnings print. Sun Pharma Q4 FY26 results in May 2026 will validate whether the US specialty pivot is genuinely transforming the company’s earnings quality.

The market is also watching closely because Q4 is the full-year wrap-up quarter — meaning the annual results, dividend recommendation, and FY27 outlook commentary all arrive on the same date. Management tone on demand environment, pricing, and deal pipeline will shape investor expectations for the next 6–12 months, not just the next quarter.

Sun Pharmaceutical Q4 FY26 Earnings Estimates

Sun Pharmaceutical Q4 FY26 — Revenue, PAT, margin and growth estimates from leading brokerages

Access premium research pieces and stock recommendations on Univest.

Here is what leading brokerages are estimating for Sun Pharmaceutical Q4 FY26 results:

Metric	Q3 FY26 (Actual)	Q4 FY26 (Estimate)
Revenue (Rs. Cr)	13,326	Rs. 13,800 – 14,700
Net Profit / PAT (Rs. Cr)	2,893	Rs. 2,800 – 3,300
Margin	EBITDA 27.2%	EBITDA 26 – 28%
CC / Volume Growth	Prior quarter	+6–10% Revenue YoY (est.)
Dividend (FY26)	Rs. 5.5/share (FY26 interim)	Rs. 4 – 6 final (est.)

Estimates compiled from MOFSL, YES Securities, JM Financial. Actual figures from NSE/BSE filings. Verify before investing.

The estimates above represent analyst consensus. Actual results could diverge — positively or negatively — based on one-time items, currency movements, and sector-specific developments. The key number to watch, beyond the headline PAT, is management’s commentary on FY27 guidance.

Screen and track Sun Pharmaceutical fundamentals on Univest Screener.

5 Key Factors That Will Drive Sun Pharmaceutical Q4 FY26 Performance

US Specialty Revenue — Ilumya and Winlevi Growth

Sun Pharma’s US specialty business is its most important growth driver and margin contributor. Ilumya (tildrakizumab, for psoriasis) and Winlevi (clascoterone, for acne) are the flagship specialty products. Q4 prescription data and net revenue realisation from these products will determine whether the US specialty narrative continues to gain momentum.

India Formulations Business

India domestic formulations contribute approximately 30% of revenue and are growing at 10–12% YoY. Q4 typically benefits from seasonal demand patterns — particularly in dermatology and cardiovascular therapy areas where Sun Pharma is market-leading. Analyst consensus expects steady 10%+ growth.

R&D Pipeline — Clinical Stage Assets

Sun Pharma has a meaningful late-stage R&D pipeline in dermatology and ophthalmology. Any Phase 3 clinical data readouts or regulatory filings (ANDA, NDA) in Q4 would be a positive catalyst. The company spends approximately 8–9% of revenue on R&D annually — one of the highest ratios in Indian pharma.

US Generics Base Business Stability

The generics business in the US — while commoditised — provides revenue scale. Stable pricing and volume in the generics portfolio in Q4 allows Sun Pharma to continue funding its specialty build-up without EPS dilution.

Emerging Markets — Rest of World Revenue

Sun Pharma has meaningful revenue from emerging markets — particularly Russia, MENA, and Southeast Asia — that provide geographic diversification. Q4 performance in these markets, which have been less affected by IT sector uncertainties, will support overall revenue growth.

5 Risks to Watch in Sun Pharmaceutical Q4 FY26

US FDA Warning Letter or Import Alert Risk

Regulatory risk is the most significant binary risk for any Indian pharmaceutical company. A US FDA warning letter or import alert on any Sun Pharma manufacturing facility — particularly its specialty manufacturing plants — would have an immediate and material impact on US revenue.

Specialty Product Pricing Pressure

US specialty drug pricing is under increasing legislative and commercial scrutiny. Medicare drug price negotiation, PBM pricing pressures, and biosimilar competition (for biologics in the pipeline) are long-term headwinds for the pricing power of specialty drugs.

R&D Failure Risk — Pipeline Assets

Clinical-stage pharmaceutical assets carry inherent failure risk. Any Phase 3 clinical trial failure in Sun Pharma’s dermatology or ophthalmology pipeline would write off years of R&D investment and remove a key growth driver from the long-term model.

Currency Risk — USD Revenue Reporting

Sun Pharma earns approximately 50% of revenue in USD and other foreign currencies. A strengthening INR would reduce reported revenue and PAT in rupee terms, even if operational performance is strong.

Competition in Specialty Dermatology

The psoriasis market — where Ilumya competes — has multiple strong competitors including Humira biosimilars, Skyrizi, and Tremfya. Maintaining and growing Ilumya’s market share requires continued investment in medical affairs and direct-to-physician marketing, which limits operating leverage.

Sun Pharmaceutical Share Price and Analyst Ratings

Sun Pharmaceutical share price snapshot and analyst ratings heading into Q4 FY26 results

Sun Pharmaceutical shares are trading at ~Rs. 1,680 as of late March 2026. The 52-week high stands at Rs. 1,960 and the 52-week low at Rs. 1,440. One-year return is -5%, against a market cap of ~Rs. 4.03 Lakh Cr.

Here is where leading brokerages stand on Sun Pharmaceutical heading into Q4 FY26 results:

Brokerage	Rating	Target Price	Key Thesis
Motilal Oswal	Buy	Rs. 1,980	Specialty portfolio driving US margin expansion
CLSA	Outperform	Rs. 2,050	Ilumya + Winlevi: multi-year specialty growth
Kotak Institutional	Buy	Rs. 1,900	India formulations + US generics balance
Bernstein	Outperform	Rs. 1,950	Best-in-class Indian pharma; R&D optionality

Source: Publicly available analyst notes, March–April 2026. For informational purposes only.

For live TCS, Infosys, and sectoral Q4 results coverage, download the

Download the Univest iOS App or Univest Android App to get live Q4 result alerts and SEBI-registered research directly on your phone.

Conclusion

Sun Pharma Q4 FY26 results in May 2026 will validate whether the US specialty pivot is genuinely transforming the company’s earnings quality. Revenue of Rs.13,800–14,700 crore and EBITDA margins of 26–28% are expected. The pivotal metric is US specialty revenue growth — if Ilumya and Winlevi continue to gain share, the re-rating from a generics company to a specialty-led pharma powerhouse will continue. At Rs.1,680 and down only 5% in one year, Sun Pharma is the defensive quality pick in Indian pharma.

This article is for informational and educational purposes only. Investments in securities are subject to market risk. Please read all related documents before investing. Past performance is not indicative of future results.

For more Q4 earnings previews across IT, banking, auto, and pharma sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Sun Pharmaceutical Q4 results 2026 date?

The Sun Pharmaceutical Q4 results 2026 date is May 12, 2026 (Expected). The board will meet to approve the audited Q4 FY26 financial results — covering the quarter ended March 31, 2026 — and will consider a dividend recommendation for FY26.

What is the Sun Pharmaceutical Q4 FY26 PAT estimate?

Analysts estimate Sun Pharmaceutical Q4 FY26 net profit (PAT) in the range of Rs.Rs. 2,800 – 3,300 crore. This estimate is based on revenue assumptions of Rs.Rs. 13,800 – 14,700 crore and a margin of EBITDA 26 – 28%. Actual results may differ from these consensus estimates.

What is Sun Pharmaceutical’s current share price ahead of Q4 results?

Sun Pharmaceutical shares are trading at approximately ~Rs. 1,680 as of late March 2026. The 52-week high is Rs. 1,960 and the 52-week low is Rs. 1,440. The one-year return is -5% and the market cap stands at ~Rs. 4.03 Lakh Cr.

Will Sun Pharmaceutical declare a dividend in Q4 2026?

Sun Pharmaceutical is expected to consider a dividend recommendation at the May 12, 2026 (Expected) board meeting. FY26 dividends paid so far total Rs. 5.5/share (FY26 interim). Analysts estimate the Q4 final or additional dividend at Rs. 4 – 6 final (est.) per share, subject to board approval and shareholder ratification at the AGM.

Which analysts have a Buy rating on Sun Pharmaceutical before Q4 results?

Motilal Oswal (Buy, TP: Rs. 1,980); CLSA (Outperform, TP: Rs. 2,050); Kotak Institutional (Buy, TP: Rs. 1,900); Bernstein (Outperform, TP: Rs. 1,950). These ratings are based on publicly available analyst notes from March–April 2026. They are for informational purposes only and not a recommendation.

What were Sun Pharmaceutical Q3 FY26 results?

Sun Pharmaceutical Q3 FY26 results showed revenue of Rs.13,326 crore and PAT of Rs.2,893 crore. Margins were at EBITDA 27.2%. Q4 is expected to show a different picture — review the estimates table in this article for full expectations.

When do Infosys and TCS announce Q4 results 2026?

TCS Q4 results 2026 date is April 9, 2026. Infosys Q4 results date is April 23, 2026. HCL Technologies reports on April 21. Read full Q4 previews for all these companies on Univest Blogs.

Is Sun Pharmaceutical a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Sun Pharmaceutical has both compelling factors and genuine near-term risks — both are covered in detail in this article. Consult a SEBI-registered financial advisor before making any investment decision. Use the Univest Screener to assess Sun Pharmaceutical fundamentals independently before investing.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings, MOFSL, YES Securities, JM Financial, Screener.in and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.